Ajai Chari, MD

Dr Chari is a Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office.

Clinical Interests: Plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). Dr Chari has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally.

Research Interests: Dr Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials as well as the national and international PI of several industry sponsored studies.

As the Director of Clinical Research in the Multiple Myeloma Program, he oversees a program renowned nationally not only for high volume patient accruals but also rigorous quality assurance. The program has played a pivotal role in the approval of each of the 5 most recent drugs to be approved by the FDA for the treatment of multiple myeloma.